Oncology and Therapy最新文献

{"title":"First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307.","authors":"Zhijie Wang, Xinmin Yu, Jun Zhao, Yan Yu, Jingxun Wu, Rui Ma, Zhiyong Ma, Jiuwei Cui, Jiayuan Zhang, Yuanyuan Bao, Shiangjiin Leaw, Jie Wang","doi":"10.1007/s40487-026-00424-z","DOIUrl":"10.1007/s40487-026-00424-z","url":null,"abstract":"<p><strong>Introduction: </strong>Squamous nonsmall cell lung cancer (sq-NSCLC) is challenging to treat, with shorter survival when compared with other NSCLC subtypes. Tislelizumab has demonstrated efficacy when combined with chemotherapy for sq-NSCLC. We report 4-year follow-up results from the phase 3 randomized RATIONALE-307 trial evaluating tislelizumab plus chemotherapy as first-line treatment for advanced or metastatic sq-NSCLC.</p><p><strong>Methods: </strong>Patients with treatment-naive advanced or metastatic sq-NSCLC were randomized to receive tislelizumab plus paclitaxel/carboplatin (arm A), tislelizumab plus nab-paclitaxel/carboplatin (arm B), or paclitaxel/carboplatin alone (arm C) until disease progression/intolerable toxicity. Crossover was permitted from arm C to tislelizumab monotherapy. The primary end point was progression-free survival (PFS) per independent review. Key secondary end points included overall survival (OS) and safety.</p><p><strong>Results: </strong>At median OS follow-up of 44.8 months, tislelizumab plus chemotherapy demonstrated durable survival benefit. Median PFS was 7.7 months (95% confidence interval [CI] 6.7-9.9) in arm A, 9.5 months (95% CI 7.4-10.1) in arm B, and 5.5 months (95% CI 4.2-5.6) in arm C. Median OS was 26.1 months (95% CI 19.0-33.8) in arm A, 23.3 months (95% CI 18.8-26.4) in arm B, and 19.4 months (95% CI 16.0-23.4) in arm C. The 4-year OS rates were 32.2%, 26.0%, and 19.2% for arms A, B, and C, respectively. Crossover occurred in 58.7% of patients from arm C. OS and PFS benefits were observed across most subgroups. Grade ≥ 3 treatment-emergent adverse events occurred in 89.2%, 89.0%, and 84.6% of patients in arms A, B, and C, respectively. No new safety signals emerged.</p><p><strong>Conclusions: </strong>At 4-year follow-up, patients with advanced sq-NSCLC who received tislelizumab plus chemotherapy experienced long-term OS and PFS benefits versus chemotherapy alone, despite high crossover rates. The combination was well-tolerated with no new safety concerns. This regimen may be a promising first-line treatment option for patients with advanced or metastatic sq-NSCLC.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT03594747.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"811-825"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor^® (Mechlorethamine) in the Treatment of CTCL.","authors":"Brian Poligone, Christopher Pullion, Adam Rumage, Richard Straube, Oreola Donini, Christopher J Schaber, Elaine S Gilmore","doi":"10.1007/s40487-026-00430-1","DOIUrl":"10.1007/s40487-026-00430-1","url":null,"abstract":"<p><strong>Introduction: </strong>Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL), a malignant and chronic skin disease. Early-stage MF has a generally favorable prognosis, but effective and well-tolerated skin-directed therapies are crucial for management. HyBryte™ is a photodynamic therapy of topical hypericin that was recently shown to be well tolerated and efficacious in early-stage CTCL. Valchlor^® (mechlorethamine) is an approved second-line therapy for use in early-stage CTCL after other topical therapies. This study compared Valchlor^® to HyBryte™ following 12 weeks of treatment. The objectives in this study were (i) to obtain preliminary comparative assessment of safety and efficacy of Valchlor^® versus HyBryte™ through 12 weeks of treatment, and (ii) to better understand the impact of HyBryte™ application on the measurement of modified Composite Assessment of Index Lesion Severity (mCAILS).</p><p><strong>Methods: </strong>This was an open-label trial enrolling 10 patients with CTCL (stage IA, IB, or IIA) randomized 1:1 to receive topical HyBryte™ or topical Valchlor^® for 12 weeks.</p><p><strong>Results: </strong>The overall response rate (ORR, i.e., complete responders + partial responders) was 60% (3/5) in the HyBryte™ treatment group and 20% (1/5; not significant) in the Valchlor^® treatment group over 12 weeks. HyBryte™ demonstrated no local adverse events at application sites, while 60% (3/5) of patients treated with Valchlor^® had skin reactions, including one case which led to study withdrawal.</p><p><strong>Conclusions: </strong>This is a single-center, open-label study. It is a pilot study requiring additional research to confirm its results. This study demonstrated the favorable safety and efficacy profile of HyBryte™ compared to Valchlor^® in patients with CTCL. HyBryte™ showed higher treatment success rates and was better tolerated.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT06149247; registered November 20, 2023.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"693-705"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13304374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occupational Variation in the Incidence of Laryngeal Cancer in the Nordic Countries.","authors":"Timo Carpén, Zakarya Hadj-Allal, Rayan Nikkilä, Johnni Hansen, Sanna Heikkinen, Elsebeth Lynge, Jan Ivar Martinsen, Jenny Selander, Ingrid Sivesind Mehlum, Marcin W Wojewodzic, Jóhanna Eyrún Torfadottir, Antti Mäkitie, Eero Pukkala","doi":"10.1007/s40487-026-00436-9","DOIUrl":"10.1007/s40487-026-00436-9","url":null,"abstract":"<p><strong>Introduction: </strong>Laryngeal cancer (LC) constitutes almost one third of the head and neck cancers, and its main risk factors, alcohol use and smoking, are well established. Our aim was to explore the variation in the incidence of LC between different occupations.</p><p><strong>Methods: </strong>This study was based on data from the Nordic Occupational Cancer Study (NOCCA), involving 14.9 million individuals from Denmark, Finland, Iceland, Norway, and Sweden. Occupational data from censuses were linked to cancer registry data from a period of up to 45 years (21,166 LC diagnoses) using personal identity codes. Standardized incidence ratios (SIRs) were calculated for different occupations, using the respective national populations as a reference.</p><p><strong>Results: </strong>Of the 21,166 patients with LC, 18,488 (87%) were men. The highest SIRs in men were noted among waiters (3.31, 95% confidence interval [CI] 2.69-4.02), beverage workers (2.51, 95% CI 1.91-3.24), and cooks and stewards (2.25, 95% CI 1.82-2.74). Among women, the highest SIRs were observed among building hands (7.37, 95% CI 3.53-13.55) and public safety workers (3.60, 95% CI 1.17-8.40). Farming and teaching occupations showed reduced SIRs in both sexes. The SIRs among male farmers, teachers, gardeners, and technical workers were reduced in all countries. The SIRs remained elevated and stable among cooks and stewards, waiters, packers, seamen, sales agents, and economically inactive males across the three 15-year periods from 1961 to 2005.</p><p><strong>Conclusion: </strong>The study confirms a major variation in the incidence of LC between occupations. The findings underscore the importance of considering lifestyle factors typical of each occupation in cancer risk assessments and the potential benefits of targeted prevention efforts.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"707-720"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13303999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas.","authors":"Pier Luigi Zinzani, Rhys Williams, Mei Xue, Binod Neupane, Priccila Zuchinali, Kyle Fahrbach, Heather Burnett, Dennis Sadic, Leyla Mohseninejad, Keri Yang","doi":"10.1007/s40487-026-00425-y","DOIUrl":"10.1007/s40487-026-00425-y","url":null,"abstract":"<p><strong>Introduction: </strong>Bruton tyrosine kinase inhibitor (BTKi) monotherapies have improved patient outcomes in B cell lymphomas; however, evidence on their comparative efficacy remains limited. This meta-analysis compared the efficacy of BTKi monotherapies across treatment naïve (TN) and/or relapsed and refractory (R/R) B cell lymphomas.</p><p><strong>Methods: </strong>Clinical trials reporting complete response (CR) or overall response rate (ORR) for zanubrutinib, acalabrutinib, or ibrutinib monotherapy in chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Waldenström macroglobulinemia (WM) were included. Response rates from similar duration of follow-up were pooled across applicable studies. Naïve odds ratios (ORs) comparing CR and ORR of zanubrutinib with acalabrutinib or ibrutinib were calculated within each B cell lymphoma indication and then meta-analyzed across all indications using a random effects model.</p><p><strong>Results: </strong>The meta-analysis found zanubrutinib to be associated with statistically significant improvements in investigator-assessed CR and ORR vs acalabrutinib and ibrutinib across B cell lymphomas, using data with similar duration of follow-up. The pooled OR estimates [95% CI] for CR were 1.80 [1.03, 3.13] for zanubrutinib vs acalabrutinib and 2.85 [1.16, 7.04] for zanubrutinib vs ibrutinib across all B cell indications. ORs significantly favored zanubrutinib over acalabrutinib and ibrutinib for R/R MCL, and over ibrutinib for R/R MZL. The pooled OR estimates for ORR were 1.59 [1.00, 2.53] for zanubrutinib vs acalabrutinib and 2.25 [1.40, 3.61] for zanubrutinib vs ibrutinib. ORs significantly favored zanubrutinib over acalabrutinib and ibrutinib for TN CLL, and over ibrutinib for R/R MCL and R/R MZL.</p><p><strong>Conclusion: </strong>Consistent with the results of existing head-to-head trials, zanubrutinib demonstrated either numerically or statistically significant improved CR and ORR compared to acalabrutinib and ibrutinib across B cell lymphomas. Similar trends were observed within each indication. These findings suggest that zanubrutinib is the most effective BTKi treatment option for patients across B cell lymphomas.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"639-654"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing Syrosingopine for Cancer Therapy: Lactate Trapping and ISR Sensitization as Metabolic Vulnerabilities.","authors":"Moslem Javidan, Zahra Jafari, Shahdokht Abbasiniya, Sirous Jamalzehi, Afsaneh Shafiei, Ali Khodadadi","doi":"10.1007/s40487-026-00444-9","DOIUrl":"10.1007/s40487-026-00444-9","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer cells rewire their metabolism toward aerobic glycolysis (the Warburg effect), leading to lactate production that supports tumor growth, hypoxia adaptation, and immune evasion. In this context, syrosingopine, originally developed as an antihypertensive drug, has been repurposed as a dual inhibitor of the lactate transporters MCT1 and MCT4. This dual blockade promotes intracellular lactate accumulation, perturbs NAD⁺ regeneration, and can induce bioenergetic stress, particularly when combined with mitochondrial metabolic inhibitors. Despite encouraging preclinical data, critical gaps remain regarding immunometabolic remodeling and clinical translation. This narrative review summarizes the repositioning of syrosingopine as a metabolic modulator in oncology, emphasizing mechanistic insights, preclinical efficacy, synthetic lethality with metabolic inhibitors, immunometabolic effects, and considerations for clinical development.</p><p><strong>Methods: </strong>We conducted a narrative review of English-language publications on syrosingopine from 2016 to 2026, identified through PubMed and Scopus and supplemented by manual reference screening. Eligible studies investigated syrosingopine in the context of cancer biology, tumor metabolism, immunometabolism, therapeutic mechanisms, nanoformulations, or computational repurposing.</p><p><strong>Results: </strong>Preclinical studies indicate that syrosingopine inhibits lactate efflux, reduces glycolytic flux, and depletes NAD⁺, thereby sensitizing cancer cells to biguanides such as metformin and to mitochondrial pyruvate carrier inhibitors such as UK-5099 through a synthetic lethality-like mechanism, inducing apoptosis and cell-cycle arrest. Advanced delivery systems enhance intratumoral drug accumulation, amplify metabolic stress, and remodel the immunosuppressive tumor microenvironment. At the same time, emerging data highlight context-dependent toxicities, including potential exacerbation of liver fibrosis and cardiovascular effects, which may constrain the therapeutic window.</p><p><strong>Conclusion: </strong>Syrosingopine exemplifies a preclinical \"lactate trap\"-based metabolic intervention with the potential to modulate integrated stress responses and immunometabolic pathways in glycolysis-dependent tumors. Its successful clinical repurposing will require biomarker-guided early-phase trials, optimization of nanoformulations and dosing strategies, incorporation of metabolic imaging readouts, and careful safety monitoring to address tissue-specific toxicities and metabolic plasticity. Graphical abstract available for this article.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"543-573"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era.","authors":"Amedeo Lonardo, Ming-Hua Zheng, Ralf Weiskirchen","doi":"10.1007/s40487-026-00442-x","DOIUrl":"10.1007/s40487-026-00442-x","url":null,"abstract":"<p><p>Metabolic disorders are risk factors for hepatocellular carcinoma (HCC) through complex proinflammatory, molecular, and cellular processes within a systemic dysmetabolic milieu. Despite significant advancements in the last two decades, HCC remains a challenging condition to treat. Resmetirom is a liver‑directed, selective THR‑β agonist that enhances mitochondrial β-oxidation, reduces de novo lipogenesis, improves lipid and cholesterol homeostasis, and, in preclinical HCC associated with metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH-HCC) models, attenuates midkine/lipoprotein receptor-related protein 1 (MDK/LRP1)-mediated immunosuppressive crosstalk. In this article, we discuss the possibility and rationale for repurposing Resmetirom, which has recently been approved for the treatment of MASH, to potentially suppress MASLD/MASH-HCC. This discussion considers the evolving epidemiology of HCC, the ongoing challenges in HCC treatment, and the intricate connection between thyroid hormone signaling, MASLD, and HCC.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"437-448"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147949887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telerehabilitation for Pain, Function, and Quality of Life in Patients with Cancer: A Systematic Review.","authors":"Leidy Tatiana Ordoñez-Mora, Diana Carolina Urrea-Arango, Juan Carlos Avila-Valencia, José Luis Estela-Zape, Marco Antonio Morales-Osorio, María Fernanda Serna-Orozco","doi":"10.1007/s40487-026-00431-0","DOIUrl":"10.1007/s40487-026-00431-0","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer rehabilitation improves function, quality of life, and symptom control, yet access to specialized programs is limited by geographic, financial, and systemic barriers. Telerehabilitation has emerged as a scalable alternative; however, its effectiveness across cancer types and intervention modalities remains heterogeneous.</p><p><strong>Methods: </strong>We conducted a systematic review of randomized clinical trials (RCTs) and nonrandomized comparative studies evaluating telerehabilitation in adults with cancer. Searches were performed in MEDLINE, LILACS, ScienceDirect, PEDro, Cochrane Central, Scopus, Springer, Taylor & Francis, and Google Scholar from January 1, 2010 to September 30, 2025. Two reviewers independently screened studies and extracted data. Risk of bias was assessed using the PEDro scale (RCTs) and the MINORS tool (nonrandomized studies). Given heterogeneity in measures and outcome definitions, we applied structured narrative synthesis with vote counting (SWiM/Cochrane), complemented by effect-direction and albatross plots.</p><p><strong>Results: </strong>Thirteen studies (11 randomized controlled trials and 2 nonrandomized comparative trials) were included, encompassing populations with breast, lung, and esophageal cancers, hematologic malignancies, gliomas, and mixed cohorts. Interventions were categorized into three main delivery modalities: supervised synchronous exercise via videoconferencing, web- or app-based programs incorporating remote monitoring, and telephone-based counseling. Across studies, telerehabilitation consistently demonstrated improvements in physical function (e.g., walking capacity, muscular strength, and peak VO₂) and reductions in fatigue. Effects on pain were modest and heterogeneous, while outcomes related to health-related quality of life (HRQoL) were mixed. The most pronounced benefits were observed in supervised synchronous interventions, whereas asynchronous or maintenance models exhibited diminished effects, indicating a lower likelihood of achieving functional improvement. Adherence, as reported by the primary study authors, ranged from moderate to high, and no serious adverse events attributable to the interventions were documented.</p><p><strong>Conclusion: </strong>Telerehabilitation is a safe and effective strategy to improve function and reduce fatigue in oncology, with less consistent evidence for HRQoL and pain. Supervised synchronous models provide the strongest benefits. Multicenter RCTs with standardized outcomes and longer follow-up are needed.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"597-620"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Augmenting Performance Status: A Preliminary Study of Objective Kinematic Assessment Using Motion Capture.","authors":"Christopher Wang, Ajay Prasad, Elizabeth Qi, Jonathan Pai, Jade Law, Krithika Chennapan, Grant Jirka, Peter Kuhn, Mihir Tale, Luciano Nocera, Jorge Nieva","doi":"10.1007/s40487-026-00434-x","DOIUrl":"10.1007/s40487-026-00434-x","url":null,"abstract":"<p><strong>Introduction: </strong>Understanding performance status (PS) is an essential aspect of oncologic care. PS is traditionally evaluated using the Karnofsky Performance Status (KPS) or Eastern Cooperative Oncology Group (ECOG) performance scales. Despite their ubiquity, these tools rely on subjective clinician interpretation and broad clinical categories, which contribute to poor inter-rater reliability and imprecise patient characterization. This study explores digital approaches to PS by leveraging three-dimensional video recordings and kinematic movement data to provide more objective, granular evaluations.</p><p><strong>Methods: </strong>In this single-center observational study, 34 oncology patients performed a standardized chair-to-table (CTT) movement. Of these participants, 52.9% were male and 47.1% were female. Patient movement was recorded using the Microsoft Kinect v2 sensor, which captures both color video (RGB) and depth-based skeletal tracking (Skeleton). Four oncologists independently reviewed the recordings and assigned KPS scores. Inter-rater reliability was assessed using the intraclass correlation coefficient (ICC). Pelvic acceleration metrics extracted from the Kinect data were correlated with summed KPS scores using Spearman's rank correlation.</p><p><strong>Results: </strong>The ICC for KPS scoring was 0.844 for RGB and 0.790 for Skeleton recordings, indicating good inter-rater reliability despite notable inter-observer variability. Vertical pelvic acceleration (mean and median) strongly correlated with summed KPS scores in both RGB (ρ ≈ 0.73-0.75, p < 0.0001) and Skeleton recordings (ρ ≈ 0.69-0.72, p < 0.0001). Horizontal and maximum acceleration showed weaker or nonsignificant associations.</p><p><strong>Conclusion: </strong>Kinect-derived motion capture offers an objective and reproducible approach to characterizing a patient's PS. Strong correlations between vertical pelvic acceleration and clinician-assigned KPS scores support its potential to augment both the accuracy and granularity of PS evaluation.</p><p><strong>Trial registry: </strong>ClinicalTrials.gov ID: NCT07082257.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"735-747"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13304051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Concepts in Salivary Duct Carcinoma: A Narrative Review.","authors":"Marvin C Masalunga, Patrick J Bradley, Carla van Herpen, Toshitaka Nagao, Göran Stenman, Vincent Vander Poorten, Henrik Hellquist, Silvana Di Palma, Martina Bradová, Ilmo Leivo, Alfio Ferlito, Alena Skálová","doi":"10.1007/s40487-026-00447-6","DOIUrl":"10.1007/s40487-026-00447-6","url":null,"abstract":"<p><p>Salivary duct carcinoma (SDC) is an aggressive neoplasm that typically involves the major salivary glands. This rapidly growing tumor is known to recur and metastasize to the neck nodes and to distant sites. Given its poor prognosis, researchers have focused on identifying factors and driver genomic alterations that may account for its behavior, ultimately yielding potential therapeutic targets. This review summarizes the growing body of knowledge on SDC since the publication of the latest WHO Classification of Tumors of the Head and Neck. Updates on emerging subtypes, immunohistochemical profiles, molecular alterations, and potential therapeutic targets are succinctly presented. Findings from studies on tumor immune microenvironment (TIME), which may have implications for the treatment and prognosis of SDC, are also discussed in this narrative review.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"575-595"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13304045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.","authors":"Benoît Godbert, Elisa Gobbini, Yaacoub Khalife, Chantal Decroisette, Florence Brellier, Hervé Lena, Anne Fleuriet, Maeva Zysman, Thomas Egenod, Nicolas Girard","doi":"10.1007/s40487-026-00437-8","DOIUrl":"10.1007/s40487-026-00437-8","url":null,"abstract":"<p><strong>Introduction: </strong>Nivolumab is approved for the treatment of advanced non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence Therapy (LIST) study evaluated long-term outcomes, safety and feasibility of immunotherapy rechallenge in French patients with previously treated aNSCLC in routine practice. We report the results of the final 24-month analysis.</p><p><strong>Methods: </strong>LIST was a longitudinal, prospective, observational study enrolling patients with aNSCLC who had received ≥ 1 prior line of therapy and were initiating treatment with nivolumab. Patients were classified into three cohorts according to prior immunotherapy exposure: immunotherapy-naïve (cohort 1); immunotherapy-experienced and discontinued prior immunotherapy for reasons other than immunotherapy-related toxicity (cohort 2); and discontinued because of immunotherapy-related toxicity (cohort 3). The primary endpoint was time to treatment discontinuation (TTD). Secondary endpoints included overall survival (OS), progression-free survival (PFS), response at 24 months, safety and quality of life (QoL).</p><p><strong>Results: </strong>A total of 522 patients were included (cohort 1, n = 280; cohort 2, n = 197; cohort 3, n = 45). Median TTD was 3.8, 3.2 and 3.4 months in cohorts 1, 2 and 3, respectively, with 24-month discontinuation-free rates of 7.9%, 6.0% and 7.1%. Median OS was 12.3, 9.5 and 9.8 months, and median PFS was 3.2, 2.6 and 3.9 months across cohorts 1, 2 and 3, respectively. Disease progression was the most common reason for nivolumab discontinuation. Numerically higher discontinuation-free rates were observed in patients who were younger (< 75 years), had better performance status, had non-squamous histology, were current smokers or had demonstrated prolonged benefit with prior immunotherapy. Safety outcomes were consistent with the established nivolumab profile, with no new safety signals. Among patients with available data, QoL changes were generally small.</p><p><strong>Conclusions: </strong>Consistent with results from previous analyses, this final 24-month analysis of LIST demonstrated real-world effectiveness and safety of nivolumab in patients with aNSCLC. Nivolumab rechallenge appears to be an option in selected patients, based on patient and disease characteristics and prior immunotherapy history.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier NCT04500535.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"721-734"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}